This is Dermata's first issued U.S. patent for XYNGARI™, which uses its Spongilla technology to topically treat acne - - Dermata expects to announce topline results from its STAR-1 Phase 3 XYNGARI™ ...
Living with skin that’s prone to rosacea isn’t easy ... so it shouldn’t clog pores or exacerbate acne, and it contains ceramides, which leave the skin feeling hydrated.
Arctic therapeutics raises funding from EIC Fund, Kaldbakur, and Sanos Group to advance its dementia treatment, AT-001, and acne drug, AT-004. The company aims to transform the treatment landscape for ...
This is Dermata's first issued U.S. patent for XYNGARI, which uses its Spongilla technology to topically treat acne -- Dermata expects to announce topline results from its STAR-1 Phase 3 XYNGARI clini ...